Circ re. Roxane Acquisition

RNS Number : 8101O

Hikma Pharmaceuticals Plc

11 February 2016

 

Publication of supplementary circular

London, 11 February 2016 - Hikma Pharmaceuticals PLC ("Hikma" or the "Company") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing pharmaceuticals company, has today published a supplementary combined prospectus and circular (the "Supplementary Prospectus") which is a supplement to the combined prospectus and circular published by the Company on 22 January 2016 in relation to the Acquisition and Consideration Shares (the "Prospectus").

The publication of the Supplementary Prospectus is a regulatory requirement under the Listing Rules and Prospectus Rules following the announcement made by the Company on 10 February 2016. The Supplementary Prospectus should be read in conjunction with the Prospectus. 

As required by Listing Rules 9.6.1R and 9.6.3R and Prospectus Rule 3.2.1R and 3.4.3R, a copy of the Supplementary Prospectus has been approved by the Financial Conduct Authority and published and submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/NSM .

Posting of the Supplementary Prospectus is expected to be completed on 11 February 2016.  You will find enclosed with the Supplementary Prospectus an additional Form of Proxy for use at the General Meeting to assist Shareholders in voting on the Resolutions. Shareholders may return either the original Form of Proxy or the Form of Proxy enclosed with the Supplementary Prospectus. If two or more valid but differing Forms of Proxy are delivered in respect of the same share for use at the General Meeting, the one which is last delivered (regardless of its date, its date of sending or the date of its execution) shall be treated as replacing and revoking the others as regards that share.

As set out in the announcement made by the Company on 10 February 2016, the Board continues to unanimously recommend that the Shareholders vote in favour of the Resolutions at the General Meeting, to be held at 9.00a.m. on 19 February 2016 at The Westbury, Bond Street, Mayfair, London W1S 2YF.

Capitalised terms used in this announcement have the meanings given to them in the Prospectus. The Prospectus and Supplementary Prospectus are available on the Company's website (www.hikma.com/en/investors/shareholder-services/circular-and-egm.aspx) and may be inspected at the office of the Company's counsel at Slaughter and May, One Bunhill Row, London, EC1Y 8YY.

Enquiries

Hikma Pharmaceuticals PLC Peter Speirs, Company Secretary    Susan Ringdal, Vice President, Corporate Strategy & Investor Relations	[phone] [phone]
FTI Consulting                                  Matthew Cole & Ben Atwell	[phone]

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million. 

Disclaimer

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE A PROSPECTUS OR EQUIVALENT. INVESTORS SHOULD NOT SUBSCRIBE FOR OR PURCHASE ANY SECURITIES REFERRED TO IN THIS ANNOUNCEMENT. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN INVITATION OR OFFER TO SELL OR EXCHANGE OR THE SOLICITATION OF AN INVITATION OR OFFER TO BUY OR EXCHANGE ANY SECURITIES IN THE UNITED STATES OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DO SO PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF SUCH JURISDICTION. NONE OF THE SECURITIES REFERRED TO IN THIS ANNOUNCEMENT SHALL BE SOLD, ISSUED, EXCHANGED OR TRANSFERRED IN ANY JURISDICTION IN CONTRAVENTION OF APPLICABLE LAW. THE SECURITIES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE SECURITIES ACT, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR OTHER JURISDICTION AND ARE BEING OFFERED AND SOLD IN RELIANCE UPON AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND ANY APPLICABLE STATE OR LOCAL SECURITIES LAWS. THERE WILL BE NO PUBLIC OFFERING OF SECURITIES IN THE UNITED STATES.

CITIGROUP GLOBAL MARKETS LIMITED ("CITI"), WHICH IS AUTHORISED BY THE PRUDENTIAL REGULATION AUTHORITY AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY AND THE PRUDENTIAL REGULATION AUTHORITY, IS ACTING EXCLUSIVELY FOR HIKMA AND NO ONE ELSE IN CONNECTION WITH THE ACQUISITION AND WILL NOT BE RESPONSIBLE TO ANYONE OTHER THAN HIKMA FOR PROVIDING THE PROTECTIONS AFFORDED TO CLIENTS OF CITI OR FOR PROVIDING ADVICE IN RELATION TO THE ACQUISITION OR ANY OTHER MATTERS REFERRED TO IN THIS ANNOUNCEMENT. NEITHER CITI NOR ANY OF ITS DIRECTORS, OFFICERS, REPRESENTATIVES, EMPLOYEES, ADVISERS, AGENTS OR AFFILIATES OWES OR ACCEPTS ANY DUTY, LIABILITY OR RESPONSIBILITY WHATSOEVER (WHETHER IN CONTRACT, IN TORT, UNDER STATUTE OR OTHERWISE) TO ANY PERSON WHO IS NOT A CLIENT OF CITI IN CONNECTION WITH THIS ANNOUNCEMENT, ANY STATEMENT CONTAINED HEREIN, THE ACQUISITION OR OTHERWISE.

-- ENDS --

 

END

 

 

CIRMMGMZZMRGVZM